Matthew Springer, PhD
Dr. Matthew L. Springer received his BA from the University of California, Berkeley in 1985 and his PhD from Stanford University in 1992. He did postdoctoral research at Stanford and continued his research there as a senior scientist until joining the UCSF faculty in 2003, where he is currently one of two non-clinicians on the faculty of the Division of Cardiology. The close juxtaposition of his basic research background with the clinical cardiologists in the Division has resulted in an active translational research program.
Dr. Springer's research interests include cell therapy and gene therapy approaches to studying cardiovascular disease, with the goals of exploring potential treatments and understanding underlying mechanisms involved in angiogenesis, vascular function, and treatments for myocardial infarction. The laboratory is studying the therapeutic effects of ultrasound-guided bone marrow cell implantation into the heart after myocardial infarction, with a special emphasis on the therapeutic implications of the age and cardiac disease state of the cell donor. Similarly, the lab is studying the effects of age and disease on circulating angiogenic cells (sometimes called endothelial progenitor cells), with a focus on the roles of endothelial nitric oxide synthase and nitric oxide in the function of these cells. The main angiogenesis interest is how cardiac motion and cyclical forces influences angiogenic gene expression and cell behavior. Currently, a large effort involves the study of vascular reactivity using a rat model of endothelium-dependent flow-mediated vasodilation that they developed, and how vascular endothelial function is affected by exposure to secondhand smoke from tobacco and marijuana.